Role of PCSK9 inhibitors in the management of dyslipidaemia.
Indian Heart J
; 76 Suppl 1: S44-S50, 2024 Mar.
Article
in En
| MEDLINE
| ID: mdl-38195006
ABSTRACT
Proprotein convertase subtilisin kexin9 (PCSK9) inhibitors are novel agents that lower LDL cholesterol and reduce cardio-vascular event rate. Being expensive, these agents are reserved for those with high risk or very high risk of CV events and with suboptimal response to statins and ezetimibe, with or without bempedoic acid or those intolerant to statins.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
Dyslipidemias
/
Anticholesteremic Agents
Limits:
Humans
Language:
En
Journal:
Indian Heart J
Year:
2024
Document type:
Article
Country of publication:
India